drugset / Trial / NCT01815086

Radioimmunoimaging of Light Chain (AL) Amyloidosis

NCT01815086

Phase 1 Completed 30 enrolled University of Tennessee
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.

Timeline

Start
2008-12
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Anselamimab Protein / enzyme biologic 1 mg Intravenous
Subject Anselamimab Protein / enzyme biologic 74 mbq Intravenous

Indications